A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced HepatocellularCarcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations (SURF-431)
Contact:
NCT Number:
Protocol:
AAAV6810
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this Study is to find out if an investigational drug, TYRA-430, is safe and effective at treating cancer in participants with locally advanced/metastatic liver cancer and other solid tumors tumors that have a certain mutation or alteration of a type of protein located on the surface of cancer cells. Investigational drug means that it has not been approved by the United States Food and Drug Administration (US FDA) to use or to treat any disease or cancer. This is the first time that the Study Drug has been used in people.
Are you Eligible? (Inclusion Criteria)
- 18 years of age or older. - Ability to swallow oral medication.
Specialty Area(s)
Bladder Cancer , Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Cervical Cancer, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Skin cancers, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
